Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)

OBJECTIVE: The aim was to assess the safety and efficacy of up to 156 weeks of ixekizumab (an IL-17A antagonist) treatment in PsA patients. METHODS: In a phase III study, patients naïve to biologic treatment were randomized to placebo, adalimumab 40 mg every 2 weeks (ADA; active reference) or ixekiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandran, Vinod, van der Heijde, Désirée, Fleischmann, Roy M, Lespessailles, Eric, Helliwell, Philip S, Kameda, Hideto, Burgos-Vargas, Ruben, Erickson, Janelle S, Rathmann, Suchitrita S, Sprabery, Aubrey Trevelin, Birt, Julie A, Shuler, Catherine L, Gallo, Gaia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516094/
https://www.ncbi.nlm.nih.gov/pubmed/32031665
http://dx.doi.org/10.1093/rheumatology/kez684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516094/
https://www.ncbi.nlm.nih.gov/pubmed/32031665
http://dx.doi.org/10.1093/rheumatology/kez684

Ejemplares similares